Patent application number | Description | Published |
20090005442 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISORDERS - This invention is directed to a method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): | 01-01-2009 |
20090105334 | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain - This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I): | 04-23-2009 |
20090137652 | METHODS FOR NEUROPROTECTION - This invention is directed to methods for providing neuroprotection comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: | 05-28-2009 |
20090203751 | Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators - The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder. | 08-13-2009 |
20090234003 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING ANXIETY DISORDERS - This invention is directed to a method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II): | 09-17-2009 |
20090281179 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEUROPATHIC PAIN AND CLUSTER AND MIGRAINE HEADACHE ASSOCIATED PAIN - This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates: | 11-12-2009 |
20100280079 | 0NOVEL, 1,2,4-THIADIAZOLIUM DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS - The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder. | 11-04-2010 |
20110152362 | METHODS OF TREATING EPILEPTOGENESIS AND EPILEPSY - This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: | 06-23-2011 |
Patent application number | Description | Published |
20090301884 | Electrophoretic analysis system having in-situ calibration - An electrophoretic system having a plurality of separation lanes is provided with an automatic calibration feature in which each lane is separately calibrated. For each lane, the calibration coefficients map a spectrum of received channel intensities onto values reflective of the relative likelihood of each of a plurality of dyes being present. Individual peaks, reflective of the influence of a single dye, are isolated from among the various sets of detected light intensity spectra, and these can be used to both detect the number of dye components present, and also to establish exemplary vectors for the calibration coefficients which may then be clustered and further processed to arrive at a calibration matrix for the system. The system thus permits one to use different dye sets to tag DNA nucleotides in samples which migrate in separate lanes, and also allows for in-situ calibration with new, previously unused dye sets. | 12-10-2009 |
20110232356 | Electrophoretic Analysis System Having In-Situ Calibration - An electrophoretic system having a plurality of separation lanes is provided with an automatic calibration feature in which each lane is separately calibrated. For each lane, the calibration coefficients map a spectrum of received channel intensities onto values reflective of the relative likelihood of each of a plurality of dyes being present. Individual peaks, reflective of the influence of a single dye, are isolated from among the various sets of detected light intensity spectra, and these can be used to both detect the number of dye components present, and also to establish exemplary vectors for the calibration coefficients which may then be clustered and further processed to arrive at a calibration matrix for the system. The system thus permits one to use different dye sets to tag DNA nucleotides in samples which migrate in separate lanes, and also allows for in-situ calibration with new, previously unused dye sets. | 09-29-2011 |
Patent application number | Description | Published |
20100327783 | STAGGERED COMPOSITION QUANTUM WELL METHOD AND DEVICE - A light emitting device comprising a staggered composition quantum well. | 12-30-2010 |
20110133157 | SURFACE PLASMON DISPERSION ENGINEERING VIA DOUBLE-METALLIC AU/AG LAYERS FOR NITRIDE LIGHT-EMITTING DIODES - A double-metallic deposition process is used whereby adjacent layers of different metals are deposited on a substrate. The surface plasmon frequency of a base layer of a first metal is tuned by the surface plasmon frequency of a second layer of a second metal formed thereon. The amount of tuning is dependent upon the thickness of the metallic layers, and thus tuning can be achieved by varying the thicknesses of one or both of the metallic layers. In a preferred embodiment directed to enhanced LED technology in the green spectrum regime, a double-metallic Au/Ag layer comprising a base layer of gold (Au) followed by a second layer of silver (Ag) formed thereon is deposited on top of InGaN/GaN quantum wells (QWs) on a sapphire/GaN substrate. | 06-09-2011 |
20110147702 | NITRIDE BASED QUANTUM WELL LIGHT-EMITTING DEVICES HAVING IMPROVED CURRENT INJECTION EFFICIENCY - A III-nitride based device provides improved current injection efficiency by reducing thermionic carrier escape at high current density. The device includes a quantum well active layer and a pair of multi-layer barrier layers arranged symmetrically about the active layer. Each multi-layer barrier layer includes an inner layer abutting the active layer; and an outer layer abutting the inner layer. The inner barrier layer has a bandgap greater than that of the outer barrier layer. Both the inner and the outer barrier layer have bandgaps greater than that of the active layer. InGaN may be employed in the active layer, AlInN, AlInGaN or AlGaN may be employed in the inner barrier layer, and GaN may be employed in the outer barrier layer. Preferably, the inner layer is thin relative to the other layers. In one embodiment the inner barrier and active layers are 15 Å and 24 Å thick, respectively. | 06-23-2011 |
20110204328 | NITRIDE BASED DEVICES INCLUDING A SYMMETRICAL QUANTUM WELL ACTIVE LAYER HAVING A CENTRAL LOW BANDGAP DELTA-LAYER - A symmetrical quantum well active layer provides enhanced internal quantum efficiency. The quantum well active layer includes an inner (central) layer and a pair of outer layers sandwiching the inner layer. The inner and outer layers have different thicknesses and bandgap characteristics. The outer layers are relatively thick and include a relatively low bandgap material, such as InGaN. The inner layer has a relatively lower bandgap material and is sufficiently thin to act as a quantum well delta layer, e.g., comprising approximately 6 Å or less of InN. Such a quantum well structure advantageously extends the emission wavelength into the yellow/red spectral regime, and enhances spontaneous emission. The multi-layer quantum well active layer is sandwiched by barrier layers of high bandgap materials, such as GaN. | 08-25-2011 |
20140191189 | STAGGERED COMPOSITION QUANTUM WELL METHOD AND DEVICE - A light emitting device comprising a staggered composition quantum well (QW) has a step-function-like profile in the QW, which provides higher radiative efficiency and optical gain by providing improved electron-hole wavefunction overlap. The staggered QW includes adjacent layers having distinctly different compositions. The staggered QW has adjacent layers X | 07-10-2014 |
Patent application number | Description | Published |
20120114739 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS - The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds. | 05-10-2012 |
20120178744 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS - The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R | 07-12-2012 |
20120322791 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS - The present invention provides Pyrazolopyrimidine Compounds of Formula (I): | 12-20-2012 |
20130150362 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS - The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds. | 06-13-2013 |
20140323519 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER - This invention relates to novel heterocyclic compounds that are useful for treating cancer and other cellular proliferative diseases and/or disorders associated with B-Raf activity. The compounds of the invention may be illustrated by the Formula (I). (Formula (I)) | 10-30-2014 |
Patent application number | Description | Published |
20110006765 | Variable Image Resolution MR Imaging System - A system acquires frequency domain components representing MR image data. An RF coil emits RF pulses for use in acquiring multiple individual frequency components corresponding to individual data elements in a 3D storage array in which the individual frequency components are successively acquired along radii from a designated center representing an origin to a boundary of the storage array. Angles of successive radii with respect to the origin are successively changed to substantially fill the storage array volume during acquisition of an MR dataset representing an MR image. A computation processor determines the angles of successive radii with respect to the origin, in response to data representing a reduction in at least one dimension of the 3D imaging volume represented by the storage array. A storage processor stores individual frequency components, acquired using the emitted RF pulses, in corresponding individual data elements in the array. | 01-13-2011 |
20130251225 | Motion Compensated MR Imaging System - A method provides motion corrected MR image data in an MR imaging system. The method employs an imaging method for acquiring k-space data of a k-space data array during an imaging scan and the k-space data represents image data of a patient anatomical region. The method acquires k-space data associated with a central region of the k-space data array and subsequently acquires k-space data external to the central region of the k-space data array. The method acquires a motion signal indicating respiratory motion at least during the acquisition of the k-space data external to the central region and compares the motion signal with a predetermined threshold. The method identifies acquired k-space data corresponding to acquisition periods when the motion signal exceeds the threshold and excludes use of the identified acquired k-space data in image reconstruction using the remaining acquired k-space data. | 09-26-2013 |
20150260810 | Methods and Systems for Automated Magnetic Field Shimming - A method for automated magnetic field shimming in a MR imaging system includes generating RF excitation pulses in anatomy, generating slice select magnetic field gradients on a static magnetic field and generating a plurality of shimming routines. The method also includes acquiring maps of the static magnetic field between each shimming routine and determining a base function for each of the plurality of shimming coils from: (i) intermediate magnitudes and directions of the static magnetic field produced by each of the plurality of shimming coils during each shimming routine; and (ii) intermediate currents supplied to each of the plurality of shimming coils during each shimming routine. The method further includes determining updated magnitudes and directions of the static magnetic field produced by each of the plurality of shimming coils by expanding the determined base function for each of the plurality of shimming coils into low order polynomials. | 09-17-2015 |
20150301146 | Magnetic Resonance Imaging (MRI) With Auto-Detection and Adaptive Encodings For Offset Frequency Scanning - Example apparatus and methods provide improved resolution over conventional magnetic resonance imaging (MRI) that is affected by the presence of metal (e.g., prosthetic hip) in the MRI field of view (FOV). Embodiments may excite a slice that is affected by a susceptibility effect produced by metal. Embodiments may excite the slice using a first pre-determined frequency and a plurality of scout frequency encodings. Embodiments may acquire nuclear magnetic resonance (NMR) signal data from the slice in response to the first pre-determined frequency and the plurality of scout frequency encodings and select frequency encodings to use to image the slice as a function of an amplitude of the NMR signal data. Frequency encodings are selected to produce data that will help account for distortions caused by the susceptibility effect. | 10-22-2015 |
Patent application number | Description | Published |
20130089537 | METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 - This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation. | 04-11-2013 |
20130115227 | ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF - Disclosed are antibodies that bind amyloid beta-derived diffusible ligands, also known as ADDLs. The antibodies are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs. | 05-09-2013 |
20130130288 | Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers - This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease. | 05-23-2013 |
20140106380 | METHODS FOR IDENTIFYING INHIBITORS OF ABETA42 OLIGOMERS - The invention herein is directed to immunoassays for the detection of Aβ42 oligomers. The inventive assays are based on the observations herein that the presence of Aβ42 oligomers in a preparation is directly related to a decrease in a C-terminal (CT) immunosignal and a correlated increase in an N-terminal (NT) immunosignal, relative to the immunosignal generated in the absence of Aβ42 oligomers, in an Aβ42 CT and NT ELISA assay and an Aβ42 CT AlphaLISA assay. The invention herein involves the use of these assays alone or in combination to screen for inhibitors of Aβ42 oligomerization. | 04-17-2014 |
20150023952 | ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF - The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs. | 01-22-2015 |
Patent application number | Description | Published |
20090012466 | Terminal Sterilization of Prefilled Containers - A method for inhibiting adverse reaction of the contents of a prefilled container during a radiation sterilization procedure is disclosed. In the method, a container which is made of a material including a radiation stable polyolefin is prefilled with a medium prior to being subjected to a gamma irradiation sterilization treatment. By using a radiation stable polyolefin material as the container, such as a polyolefin with a radiation stabilizer additive, and by prefilling the container prior to the gamma irradiation treatment, the container can be effectively sterilized without adversely affecting its contents. | 01-08-2009 |
20100331465 | TPE COMPOSITION HAVING GOOD CLARITY AND LOW HARDNESS AND ARTICLES FORMED THEREFROM - A thermoplastic elastomer (TPE) composition is provided which has a first high vinyl styrenic block copolymer (SBC) having a number average molecular weight (Mn) less than about 120,000 Daltons (Da) and a second high vinyl SBC having a Mn greater than about 120,000 Da; a polyolefin; and a plasticizer compatible with the first and second SBCs. An article formed from such a TPE composition has a tensile strength greater than 600 psi, a hardness less than 45 Shore A, and a haze less than 20 percent, preferably less than 15 percent, when the thickness of the article is 1.7 mm, and wherein the physical dimensions of the article remain substantially unchanged after immersion of the article in boiling water for one hour. | 12-30-2010 |
20120058351 | Coating System, Articles and Assembly Using the Same and Methods of Reducing Sticktion - The present invention provides a coating system for an article including a first component having a surface in frictional engagement with a surface of a second component, wherein at least a portion of at least one surface of the component(s) is coated with a coating prepared from a composition including a first, curable organopolysiloxane comprising at least two alkenyl groups; and a second, curable organopolysiloxane comprising at least two polar groups, the second organopolysiloxane being different from the first organopolysiloxane, which can provide low breakloose force when used in syringe assemblies. | 03-08-2012 |
20120143148 | Sealing Members, Articles Using the Same and Methods of Reducing Sticktion - The present invention provides rubber sealing members having an exterior surface adapted to sealingly engage an inner surface of a chamber of the medical device, the exterior surface of the sealing member having a coating thereon prepared from a curable composition including: (a) a first organopolysiloxane having at least two alkenyl groups; and (b) a second organopolysiloxane having at least two pendant hydrogen groups, the second organopolysiloxane being different from the first organopolysiloxane, wherein at least one of the first organopolysiloxane, the second organopolysiloxane or an optional third organopolysiloxane of the curable composition comprises a fluoro group. | 06-07-2012 |
20140052076 | Sealing Members, Articles Using the Same and Methods of Reducing Sticktion - The present invention provides rubber sealing members having an exterior surface adapted to sealingly engage an inner surface of a chamber of a medical device, the exterior surface of the sealing member having a coating thereon prepared from a curable composition including: (a) a first organopolysiloxane having at least two alkenyl groups; and (b) a second organopolysiloxane having at least two pendant hydrogen groups, the second organopolysiloxane being different from the first organopolysiloxane, wherein at least one of the first organopolysiloxane, the second organopolysiloxane or an optional third organopolysiloxane of the curable composition comprises a fluoro group. | 02-20-2014 |
20160082193 | PHARMACEUTICAL SYRINGE PISTON - A pharmaceutical syringe piston having a longitudinal axis includes a body having a central face portion with a first outer circumference and maximum first diameter. A cylindrical sealing portion proximate the central face portion has first and second axial ends and a wall extending therebetween. The wall has a second outer circumference and a second diameter essentially constant along the longitudinal axis between the first and second axial ends of the cylindrical sealing portion and is larger than the maximum first diameter. An annular curved portion has a maximum outer diameter less than the second diameter and connects the first axial end of the cylindrical sealing portion to the first outer circumference. An inert film encloses the central face portion and at least a part of the annular curved portion and has an outer boundary between the first axial end of the cylindrical sealing portion and the first outer circumference. | 03-24-2016 |
Patent application number | Description | Published |
20090258853 | Somatostatin Agonists - This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. | 10-15-2009 |
20090270451 | Piperdine Glycine Transporter Inhibitors - The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved. | 10-29-2009 |
20100168097 | Non-Nucleoside Reverse Transcriptase Inhibitors - Compounds of Formula I: Formula (I); are HIV reverse transcriptase inhibitors, wherein R | 07-01-2010 |
20100222322 | Non-Nucleoside Reverse Transcriptase Inhibitors - Indole compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein R | 09-02-2010 |
20130005744 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved. | 01-03-2013 |
20130084346 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved. | 04-04-2013 |
20130196002 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved. | 08-01-2013 |
20140303143 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS - Disclosed are compounds of Formula (A) or a salt thereof, wherein “Het”, R | 10-09-2014 |
20150299227 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS - The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved. | 10-22-2015 |